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AbstrAct
Objective Tight glycemic control and aggressive 
treatment of additional cardiovascular risk factors can 
substantially reduce risk of diabetes-related complications. 
In 2013, the Swiss Society of Endocrinology and 
Diabetology (SSED) established national criteria on good 
disease management in diabetes, but little is known 
about compliance in clinical care. Here we assessed to 
what extent patients from two tertiary care centers in the 
German-speaking part of Switzerland enrolled in the Swiss 
Diabetes (SwissDiab) Registry adhere to the SSED criteria.
Research design and methods SwissDiab is a 
prospective observational cohort study of patients 
regularly treated at Swiss tertiary diabetes centers. 
Data were collected through standardized annual health 
examinations. Baseline participant descriptive statistics, 
stratified by diabetes mellitus type 1 (DM1) and type 2 
(DM2), were compared with SSED targets for glycemic 
control, blood pressure, blood lipids, weight maintenance, 
and ophthalmic examination.
Results By the end of 2016, 604 participants with DM1 
(40%) and DM2 (60%) had data available for analyses, 
36% and 29% women, respectively. At baseline, all the 
SSED targets were met with two exceptions: a glycated 
hemoglobin A1c value <7% was measured in 32% of 
participants with DM1 (SSED target: ≥40%) and 47% and 
56% of overweight or obese participants with DM1 and 
DM2, respectively, received nutritional counseling in the 
previous year (SSED target: ≥80%).
Conclusions The SSED targets for good disease 
management in diabetes were achieved in the majority 
of participants at the time of enrollment, but results 
also highlight areas where disease management can be 
improved, particularly the role of nutrition counseling.
InTROduCTIOn
Tight glycemic control and aggressive treat-
ment of additional cardiovascular risk factors 
have shown to reduce both microvascular and 
macrovascular complications of diabetes.1–4 
This has led to treatment standards targeting 
both therapeutic and process of care parame-
ters. Benefits from adherence to such guide-
lines have been shown in several studies, 
including better glycemic control, lower 
risk of long-term morbidity and mortality, 
improved quality of life, and lower healthcare 
costs.5–8 However, studies have also shown 
great disparities between guideline objectives 
and actual standard of care.6 9 10 
Data on the current standard of diabetes 
care in Switzerland are scarce. To fill this 
gap, two tertiary diabetes care centers in 
the German-speaking part of Switzerland 
(St. Gallen and Bern) initiated the Swiss 
Diabetes (SwissDiab) Registry in 2008, a 
national multicenter project with the aim to 
prospectively collect data regarding diabetes 
management and prevalence and incidence 
of diabetes-related complications. The first 
patients were enrolled in 2010. Participants 
undergo an extensive annual health exam-
ination according to a standardized protocol. 
In 2013, the Swiss Society of Endocrinology 
and Diabetology (SSED) established national 
target criteria for good disease management 
in diabetes. The target criteria are based on 
the Diabetes Recognition Program estab-
lished by the American Diabetes Association 
significance of the study
What is already known about this subject?
 ► Standardization of diabetes management is known 
to improve quality of care.
What are the new findings?
 ► This study is the first to assess adherence to the 
Swiss national targets introduced in 2013 for good 
disease management in diabetes. Overall, the 
results reflect a high standard of diabetes care in 
two tertiary centers in the German-speaking part of 
Switzerland, but also indicate areas where disease 
management can be improved, particularly the 
implementation of nutrition counseling.
How might these results change the focus of 
research or clinical practice?
 ► We hope this study will motivate diabetes care 
centers to evaluate their clinical practices, raising 
awareness of the current standard of diabetes 
management and encouraging improvements.
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(ADA) and the National Committee for Quality Assurance 
and adapted to the treatment guidelines for Switzerland 
established by SSED in 2009.11 12 The criteria target 
clinical and biochemical parameters relevant to clinical 
outcomes of diabetes management as well as guiding 
frequencies of annual screenings and monitoring of 
diabetes-related complications.13 However, little is known 
about compliance in clinical care settings.
The aim of this study was to evaluate compliance with 
the SSED target criteria for good disease management of 
diabetes in 604 SwissDiab participants with eligible base-
line data at the time of analysis.
ReseaRCH desIgn and meTHOds
study participants
SwissDiab is an ongoing prospective observational 
cohort study enrolling patients with diabetes regularly 
seen and treated at Swiss tertiary diabetes care centers. 
Eligible are patients ≥18 years of age, regardless of 
diabetes type (gestational diabetes excluded), duration, 
or treatment. Patients with a life expectancy <1 year due 
to severe comorbidity (eg, end-stage cancer) or unable 
to comply with the study protocol (eg, due to mental 
disorder or drug abuse) are excluded at the discretion 
of the attending physician. Diabetes is defined according 
to ADA (glycated hemoglobin A1c (HbA1c)≥6.5% 
(≥48 mmol/mol) or fasting plasma glucose ≥7 mmol/L or 
random plasma glucose ≥11.1 mmol/L plus typical symp-
toms or 2-hour plasma glucose ≥11.1 mmol/L following 
a 75 g oral glucose tolerance test).14 Patients under treat-
ment with ≥2 oral hypoglycemic agents and/or insulin 
in the absence of a clinical diagnosis (as defined above) 
are also included. Diabetes type is diagnosed clinically 
in most cases, supported by autoantibody status where 
appropriate.15
The present study includes data from the two initial 
centers in the German-speaking part of Switzerland, 
the Division of Diabetes, Endocrinology, Nutritional 
Medicine, and Metabolism, Inselspital Bern, University 
Hospital, Bern, and the Division of Endocrinology and 
Diabetes at the Cantonal Hospital of St. Gallen. All partic-
ipants provided written informed consent. 
Research design and methods
Patient-related data were collected through a stand-
ardized annual health examination, comprising the 
following domains.
Diabetes-specific medical history
Information relevant to the care and management of 
diabetes (eg, diabetes type, date of diagnosis, family 
history, treatment history (including drug class and 
dosages), hypoglycemic events, and diabetes-related 
complications) was obtained from the patient history, 
supplemented by information retrieved from other 
sources like patient records where appropriate.
Clinical and anthropometric measurements
Clinical examinations were conducted by trained medical 
staff experienced in epidemiological and clinical studies. 
Weight (to the nearest 0.1 kg) was measured with partici-
pants wearing light clothes and no shoes. Height (to the 
nearest 0.5 cm) was measured using a wall-mounted stadi-
ometer. Body mass index (BMI) was calculated as weight 
(kg) divided by height (m) squared. Waist circumference 
was measured at the widest point using a non-stretchable 
tape. At baseline, systolic blood pressure (SBP) and dias-
tolic blood pressure (DBP) was measured once on each 
arm following a 5 min rest with the participant in a seated 
position. The mean of the two measurements was used.
Biochemistry
Participants arrived at the study center following an over-
night fast (≥7.5 hours), having been instructed to take 
their antihypertensive medication as prescribed. Fasted 
blood was drawn from the antecubital vein and further 
processed. HbA1c was determined using a Diabetes 
Control and Complications Trial (DCCT)/UK Prospec-
tive Diabetes Study (UKPDS) traceable assay. Serum total, 
high-density lipoprotein (HDL), and low-density lipopro-
tein (LDL) cholesterol, and triglycerides were measured 
according to routine methods at the laboratory medicine 
at each center. Aliquots of serum and whole blood were 
stored at −80°C.
Criteria for good disease management in diabetes
The SSED criteria for good disease management in 
diabetes define treatment targets in eight domains to 
guide diabetes-specific standard of care in Switzerland.13 
The current analysis focused on a subset of criteria related 
to clinical and biochemical targets, and frequencies of 
nutrition counseling and ophthalmic examination. The 
remaining treatment objectives were excluded from the 
analysis as they were either part of the SwissDiab annual 
health examination (ie, foot exam, and screening for 
neuropathy and nephropathy) and thus performed in all 
participants or information was not collected (eg, phys-
ical activity counseling if BMI ≥25 kg/m2, and smoking 
cessation counseling in active smokers). Specifically, 
compliance with the treatment targets in the following 
five domains was assessed:
1. HbA1c:
 – ≥9.0% (75 mmol/mol) in <15% of patients
 – <8.0% (64 mmol/mol) in ≥60% of patients
 – <7.0% (53 mmol/mol) in ≥40% of patients
2. BP ≥140/90 mm Hg in <35% of patients
3. LDL-cholesterol levels in patients <75 years of age:
 –  ≥3.37 mmol/L in <37% of patients
 –  <2.6 mmol/L in ≥36% of patients 
4. Annual nutrition counseling in ≥80% of patients with 
a BMI ≥25kg/m2
5. Annual standard ophthalmic examination in ≥60% of 
patients
The current analysis was based on data collected 
during the baseline annual health examination. Data 
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Table 1 Baseline characteristics of Swiss Diabetes Registry participants, stratified by diabetes type (n=604)
Characteristics n DM1 n DM2 P-diff*
Participants, % 239 39.6 365 60.4 –
Females, % 87 36.4 105 28.8 0.05
Age, years 239 39.9 (28.3–53.4) 365 62.1 (54.7–68.8) <0.0001
Age at diagnosis, years 238 18.0 (12.0–35.0) 362 48.0 (42.0–56.0) <0.0001
Years since diagnosis, years 238 15.0 (7.0–24.0) 362 12.0 (6.0–18.0) 0.0003
Higher education, %† 105‡ 44.1 99§ 27.3 <0.0001
Migration background, % 43‡ 18.1 123§ 33.9 <0.0001
BMI, kg/m2 239 24.6 (22.2–27.0) 365 32.1 (28.4–36.5) <0.0001
BMI≥25 kg/m2, % 109 45.6 341 93.4 <0.0001
Waist circumference, cm 233 91.0 (83.0–98.0) 346 110.0 (101.0–122.0) <0.0001
Systolic BP, mm Hg 236 128.0 (120.0–137.5) 363 138.0 (127.0–149.5) <0.0001
Diastolic BP, mm Hg 236 76.0 (71.5–82.8) 363 77.5 (72.0–83.5) 0.32
Current smokers, % 49‡ 20.6 71§ 19.6 0.76
HbA1c, % 239 7.4 (6.8–8.0) 365 7.1 (6.6–7.9) 0.01
HbA1c, mmol/mol 239 57.4 (50.8–63.9) 365 54.1 (48.6–62.8) 0.01
Triglycerides, mmol/L 237 0.9 (0.6–1.3) 363 1.9 (1.2–2.8) <0.0001
Total cholesterol, mmol/L 238 4.5 (4.0–5.3) 363 4.1 (3.6–4.9) <0.0001
HDL-cholesterol, mmol/L 238 1.6 (1.3–2.0) 363 1.1 (1.0–1.3) <0.0001
LDL-cholesterol, mmol/L 238 2.6 (2.2–3.1) 363 2.4 (1.9–2.9) <0.0001
Data are median (IQR), or frequency (%). 
*Two-sided Wilcoxon rank-sum test for continuous and χ2 test for categorical variables.
†College or university degree.
‡  Information missing in one participant.
§Information missing in two participants.
BMI, body mass index; BP,  blood pressure; DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; HbA1c, glycated hemoglobin A1c; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
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from both study centers were pooled and analyses were 
stratified by diabetes mellitus type 1 (DM1) and type 2 
(DM2). In secondary analyses, further stratification was 
done by time since diagnosis (≤5 years or >5 years) to 
explore whether diabetes duration influences treat-
ment outcomes. Descriptive statistics were computed 
as medians and IQR for continuous variables and 
percentages for dichotomous variables. Between-group 
differences were determined using two-sided Wilcoxon 
rank-sum test for continuous variables and χ2 test for 
categorical variables. All analyses were performed using 
SAS V.9.3 (SAS Institute).
ResulTs
Baseline participant characteristics
By 31 December 2016 data for 674 SwissDiab partici-
pants were available for analysis, 55% (n=371) of them 
recruited in St. Gallen and 45% (n=303) in Bern, consti-
tuting 248 cases (37%) of DM1, 375 cases (55%) of DM2, 
and 51 cases (8%) of rarer forms of diabetes (eg, mono-
genic and drug-induced diabetes). The latter group was 
excluded from the analysis. Participants lacking HbA1c 
(2%) or with implausible data (BMI <15 or >90 kg/
m2 (1%)) were excluded, leaving 239 participants with 
DM1 and 365 participants with DM2 eligible for analysis. 
Baseline descriptive characteristics of the 604 SwissDiab 
participants included in the analysis are shown in table 1.
Compliance with ssed criteria for good disease management 
of diabetes
Table 2 shows the proportion of SwissDiab participants 
fulfilling the criteria for good glycemic and BP control 
established by the SSED.13 The proportion of participants 
with an HbA1c≥9%, and an HbA1c<8% comply with the 
SSED targets (<15% and ≥60%, respectively), regardless 
of diabetes type and with no statistically significant differ-
ence between the DM1 and DM2 group. The SSED target 
of an HbA1c<7% in ≥40% of patients was only achieved 
in the group with DM2. The proportion of participants 
with high BP (≥140/90 mm Hg) was within the SSED 
target (<35%) in both the DM1 and DM2 groups.
As shown in table 3, although the SSED targets for 
LDL-cholesterol levels in patients <75 years of age were 
achieved in both the DM1 and DM2 groups, the propor-
tion tended to be greater in the DM2 group.
Regardless of diabetes type, the majority of participants 
underwent at least one ophthalmic examination during 
the year prior to the baseline SwissDiab examination. 
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Table 2 Proportion of Swiss Diabetes Registry participants fulfilling the Swiss Society of Endocrinology and Diabetology 
(SSED) criteria for glycemic and blood pressure (BP) control at baseline, stratified by diabetes type (n=604)
SSED Criterion SSED target (%)
DM1
(n=239)
DM2
(n=365) P-diff
HbA1c≥9% (75 mmol/mol) <15 n=20, 8% n=28, 8% 0.76
HbA1c<8% (64 mmol/mol) ≥60 n=179, 75% n=281, 77% 0.56
HbA1c<7% (53 mmol/mol) ≥40 n=76, 32% n=159, 44% 0.004
BP≥140/90 mm Hg <35 n=7*, 3% n=28†, 8% 0.02
Group estimates that meet the SSED targets are highlighted in bold. Between-group differences determined with the  χ2 test. 
*Information missing in three participants.
†Information missing in two participants. 
DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; HbA1c, glycated hemoglobin A1c.
Table 3 Proportion of Swiss Diabetes Registry participants <75 years of age fulfilling the Swiss Society of Endocrinology and 
Diabetology (SSED) criteria for low-density lipoprotein (LDL)-cholesterol at baseline, stratified by diabetes type
LDL-cholesterol SSED target (%)
DM1
(n=235)*
DM2
(n=336)† P-diff
≥3.37 mmol/L <37 n=43, 18% n=43, 13% 0.07
<2.6 mmol/L ≥36 n=112, 48% n=198, 59% 0.008
Group estimates that meet the SSED target criteria are highlighted in bold. Between-group differences determined with the χ 2  test. 
*One participant excluded due to missing LDL-cholesterol data. 
†Two participants excluded due to missing LDL-cholesterol data. 
DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2.
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The SSED target of ≥80% was achieved in both the DM1 
(88.4%, n=206, data missing in six participants) and DM2 
groups (90.4%, n=328, data missing in two participants), 
with no statistically significant difference between the 
groups (P-difference=0.45).
Of the 109 participants with DM1 and a BMI≥25 kg/m2, 
 information on nutrition counseling was available in 104 
participants. Of these, 47.1% (n=49) received nutrition 
counseling in the previous year. In the DM2 group, 93.4% 
(n=341) were overweight or obese, and 56.1% (n=184) 
received nutrition counseling in the previous year (infor-
mation missing in 13 overweight or obese participants). 
Neither group thus achieved the SSED target of ≥80%.
stratification based on time since diagnosis
The 39 participants diagnosed with DM1 ≤5 years ago 
(information missing for one participant) were older 
at the time of diagnosis compared with the 199 partici-
pants diagnosed >5 years ago (36.0 years (27.0–49.0) vs 
16.0 years (11.0–31.0), P-difference <0.0001) with a lower 
average HbA1c (7.0% (6.3–7.8) vs 7.4% (6.9–8.0), P-dif-
ference=0.04). Compared with the 282 participants diag-
nosed with DM2 >5 years ago (information missing for 
three participants), the 80 participants diagnosed with 
DM2 ≤5 years ago were younger (56.5 years (49.9–63.2) vs 
63.9 years (56.6–70.1), P-difference <0.0001) and received 
their diagnosis at an older age (55.0 years (46.5–60.5) 
 vs 47.0 years (41.0–54.0), P-difference <0.0001). The 
latter group had a lower average HbA1c (6.6% (6.1–7.3) 
vs 7.3% (6.7–8.0), P-difference <0.0001) and higher 
total cholesterol (4.5 mmol/L (4.0–5.4) vs 4.0 mmol/L 
(3.5–4.7), P-difference <0.0001) and LDL-cholesterol 
(2.7 mmol/L (2.1–3.3) vs 2.3 mmol/L (1.8–2.7), P-dif-
ference <0.0001) levels. The complete set of participant 
characteristics stratified by diabetes type and time since 
diagnosis are available in online supplementary table 1.
The SSED target of an HbA1c<7% in ≥40% of patients 
was achieved among participants diagnosed with DM1 ≤5 
years ago but not among participants diagnosed >5 years 
ago (P-difference=0.01). Of the 39 participants diag-
nosed with DM1 ≤5 years ago, 48.7% (n=19) fulfilled the 
SSED criterion of an HbA1c<7%, achieving the SSED 
target of ≥40%. Among the 199 participants diagnosed 
with DM1 >5 years ago, 28.6% (n=57) fulfilled the SSED 
criterion.
Among participants with DM2, the SSED target of 
an HbA1c<7% in ≥40% of patients was achieved in the 
group of participants diagnosed with DM2 ≤5 years ago 
but not in the participants diagnosed >5 years ago (P-dif-
ference <0.0001). Of the 80 participants diagnosed with 
DM2 ≤5 years ago, 63.8% (n=51) fulfilled the SSED crite-
rion, achieving the target of ≥40%. Among the 282 partic-
ipants diagnosed with DM2 >5 years ago, 38.3% (n=108) 
fulfilled the SSED criterion.
Among participants with DM2, the SSED target of 
an LDL-cholesterol level of ≥3.37 mmol/L in <37% of 
patients was achieved in both the group diagnosed ≤5 
years ago (n=78, data missing in two participants) and >5 
years ago (n=256, data missing in two participants), but 
to a greater extent in the latter (24.4% (n=19) vs 9.4% 
(n=24), respectively, P-difference=0.0005). A similar 
 o
n
 7 February 2019 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2017-000454 on 21 February 2018. Downloaded from 
5BMJ Open Diab Res Care 2018;6:e000454. doi:10.1136/bmjdrc-2017-000454
Epidemiology/Health Services Research
result was obtained for the SSED target of an LDL-choles-
terol level of <2.6 mmol/L in ≥36% of patients, with 42.3% 
(n=33) fulfilling the criterion in the group diagnosed 
with DM2 ≤5 years ago and 64.1% (n=164) fulfilling the 
criterion in the group diagnosed with DM2 >5 years ago 
(P-difference=0.0006). No statistically significant differ-
ences in the LDL-cholesterol targets were observed in 
participants diagnoses with DM1 ≤5 years or >5 years ago.
The complete set of results stratified by diabetes type 
and time since diabetes diagnosis are available in online 
supplementary tables 2-3.
COnClusIOns
Here we analyzed baseline data of 604 SwissDiab partic-
ipants with DM1 and DM2 with respect to compliance 
with a subset of SSED national guidelines for good 
disease management in diabetes focused mainly on clin-
ical and biochemical targets.13 The results show that 
the majority of the criteria under study were achieved 
in a tertiary care setting. Exceptions were annual nutri-
tion counseling in ≥80% of patients with a BMI ≥25 kg/
m2 which was not achieved in either the DM1 or DM2 
group, and an HbA1c<7% in ≥40% of patients which was 
not reached among participants with DM1. However, 
taking into consideration duration of diabetes, the SSED 
target of an HbA1c<7% in ≥40% of patients was achieved 
among participants diagnosed ≤5 years ago, regardless 
of diabetes type. Considering participants diagnosed 
with DM2 >5 years ago, the SSED target was no longer 
met, illustrating that compliance with treatment targets 
is partly dependent on the composition of the patient 
group. Overall, the results reflect a comparably high 
standard of diabetes care among SwissDiab participants 
at the two tertiary care centers in the German-speaking 
part of Switzerland.
The sex distribution in SwissDiab was similar to that 
observed among the 392 participants (68% men and 
32% women) with DM2 in the CoLaus study, a popula-
tion-based cross-sectional study of >6000 adults living 
in Lausanne, in the French-speaking part of Switzer-
land.16 Both results are in line with national data on the 
prevalence of diabetes based on the 2012 Swiss Health 
Survey (6% among men and 4% among women) and 
earlier studies.17 18 A relatively high proportion of DM1 
compared with DM2 in SwissDiab is expected. Given the 
complexity of maintaining glycemic control in DM1, 
these patients are often referred to tertiary care which 
has more experience and expertise in treatment options 
(eg, implementation of new technologies, flexible insulin 
therapy, and diabetes education).
Epidemiological data regarding clinical characteristics 
as well as quality of care of patients with diabetes in Swit-
zerland are scarce. In the 1970s, the WHO Multinational 
Study of Vascular Disease in Diabetes was established 
with the aim to compare prevalence of vascular disease in 
diabetes.19 20 In 2009, Allemann et al conducted a 30-year 
follow-up in the 533 Swiss participants recruited by local 
practitioners.5 All-cause and cardiovascular mortality was 
higher in participants with DM1 and DM2 compared with 
the general population, but decreased during the last two 
decades, indicating improved treatment strategies.
In 2011, Gerber et al published data on 1121 
patients with DM2 treated by general practitioners in 
the four linguistic regions (German, French, Italian, 
and Romansh) of Switzerland.21 The mean HbA1c 
level was 6.9%±1.0% in the German-speaking region 
compared with 7.3%±1.1% (median 7.1% (6.6–7.9)) 
in SwissDiab. Furthermore, mean BMI (29.5±5.4 kg/
m2) as well as BP (SBP, 138.2±16.4 mm Hg; DBP, 
81.1±10.4 mm Hg) tended to be lower in the study by 
Gerber et al compared with the SwissDiab study (BMI, 
mean=32.8±6.2 kg/m2, median=32.1 kg/m2 (28.4–36.5); 
SBP, mean=138.7±16.6 mm Hg, median=138.0 mm Hg 
(127.0–149.5); DBP, mean=77.4±10.0 mm Hg, 
median=77.5 mm Hg (72.0–83.5)), suggesting that the 
metabolic profile of participants in the former study was 
better, which is not surprising given the different clinical 
settings in which the participants of the two studies were 
recruited. Mean age at diagnosis of DM2 in SwissDiab 
was 48.3±10.4 years (median 48.0 years (42.0–56.0)), and 
the mean age at start of therapy in the study by Gerber 
et al was 60.9±11.2 years. Given that antidiabetic treat-
ment is generally initiated within 1 year of diagnosis,14 
this might indicate an earlier onset and a more advanced 
and progressive course of disease in the SwissDiab partic-
ipants, which would be in line with the tertiary care 
setting in which participants were recruited. It is also 
possible that variations in diabetes therapy contribute to 
the differences; however, data on medication are not yet 
available in SwissDiab.
In 2013, Burgmann et al published a retrospective study 
comparing data of all patients with DM2 admitted to the 
general clinic of medicine at the Hospital Centre Biel 
in 2009 to the treatment recommendations published 
by the SSED the same year.12 22 Mean age was higher 
compared with the SwissDiab participants (74.2±10.8 
years vs 61.3±10.4 years, median=62.1 years (54.7–68.8)) 
as was the mean HbA1c (7.7%±1.7% vs 7.3±1.1%; 
median=7.1% (6.6–7.9)).22 The authors concluded that 
metabolic control was suboptimal in the majority of 
patients with DM2 and implementations of treatment 
guidelines by general practitioners as well as hospitals 
need to be improved. However, the results may rather 
reflect a greater disease burden of hospitalized patients 
with DM2, and as such, may not reflect a general failure 
to adhere to treatment guidelines. Burgmann et al do 
not provide detailed information on disease burden or 
the reason behind hospitalization but 44% of patients 
with DM2 presented with an HbA1c level ≤7%, which is 
similar to the proportion seen in the tertiary setting of 
SwissDiab. Furthermore, 20% had an HbA1c>8.5% (11% 
in SwissDiab), supporting the assumption that glycemic 
control in individuals with DM2 and need of hospitaliza-
tion tends to be worse compared with patients in outpa-
tient clinics.
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In 2014, Zuercher et al published baseline data from the 
CoDiab-VD Study, a population-based cohort of partic-
ipants with diabetes recruited in the French speaking 
canton of Vaud.23 Of the 519 participants, 67% were diag-
nosed with DM2. Mean age and diabetes duration were 
similar to that observed in SwissDiab. Self-reported HbA1c 
was available in 177 participants (34%) with unspeci-
fied diabetes type and was similar to baseline HbA1c 
in the SwissDiab DM1 and DM2 groups (7.3% (95% CI 
7.1 to 7.5) vs 7.5% (95% CI 7.3 to 7.6) and 7.3% (95% 
CI 7.2 to 7.4), respectively).23 The recruitment strategy 
via community pharmacies (participation rate <50%) has 
the potential to capture a more health-conscious fraction 
of the target population. Further assuming that HbA1c-
aware participants are more health-conscious and there-
fore better controlled, the HbA1c level is likely to be an 
underestimation of the population average. General prac-
titioners might measure HbA1c less frequently in patients 
with milder forms of diabetes, for example, those treated 
only with oral antidiabetic medication (51% in CoDi-
ab-VD), or might communicate good HbA1c levels less 
actively as they may not have an immediate therapeutic 
consequence. With the limited information provided, it 
is difficult to draw any conclusions regarding differences 
in disease severity between the two studies.
The SSED targets for LDL-cholesterol were met in 
both SwissDiab and the inpatients with DM2 in Burg-
mann et al.22 Lack of information in the study by Gerber 
et al and in CoDiab-VD precludes comparisons with these 
study populations.21 23 That LDL-cholesterol was better 
controlled in the DM2 compared with the DM1 group 
is to be expected as cardiovascular risk is higher in DM2 
compared with DM1 in the absence of secondary compli-
cations. Therefore, one can assume that the proportion 
of participants on statins was higher in the DM2 group. 
Higher mean total and LDL-cholesterol levels in partic-
ipants diagnosed with DM2 ≤5 years ago were unex-
pected. Given the better glycemic control in this group, 
one possible explanation is that healthcare professionals 
in charge are less stringently targeting lipids. Suboptimal 
adherence to prescribed lipid-lowering medications 
might also be an explanation. However, information on 
medication is not yet available for analysis in SwissDiab.
Out of 511 participants in CoDiab-VD, 58% attended 
an ophthalmic examination during the previous year,23 
whereas the SSED target of ≥80% was achieved in Swiss-
Diab. How representative these results are to the primary 
care setting is unclear. It is possible that patients with 
more severe diabetes, as often is the case in tertiary 
settings, are more carefully screened.
The SSED criterion regarding weight maintenance 
addresses the importance of raising patient awareness 
of the central role of weight and diet for good diabetes 
management through annual discussions with the 
healthcare provider. In CoDiab-VD, written or verbal 
diet recommendations were received by 49% of the 
participants.23 Distinction between DM1 and DM2, or 
based on BMI category was not provided, preventing 
direct comparisons with SwissDiab, where 47% and 56% 
of overweight/obese participants with DM1 and DM2, 
respectively, received nutrition counseling. Irrespectively, 
this area of diabetes care and management can clearly be 
improved. The primary focus of the SSED criteria is the 
primary care setting, where fostering of healthy lifestyle 
choices likely has the potential to substantially reduce 
the risk of future need of tertiary care, improve quality of 
life and reduce the burden on healthcare systems. Future 
studies assessing compliance in the primary care setting 
are therefore warranted.
Applying diabetes care targets primarily aimed at the 
primary care setting to tertiary care could be considered 
too stringent as the patient group of the latter likely 
includes patients with a more advanced and progressive 
course of disease where, for example, glycemic control 
is likely harder to achieve. On the other hand, benefits 
of intensive multifactorial therapy in reducing micro-
vascular and/or macrovascular complications have 
been shown,2 24–26 and might thus be beneficial to the 
high-risk patient group with diabetes treated in tertiary 
care. As this study illustrates, it is possible to adhere to 
the majority of the SSED targets in this high-risk patient 
group. However, although shown to be beneficial, inten-
sive therapy including tight glycemic control has also 
been associated with increased mortality in high-risk 
individuals with DM2,27 emphasizing that on the indi-
vidual level, treatment goals should always be based on 
patient-specific characteristics, including risk of hypo-
glycemia, diabetes duration, life expectancy, comorbidi-
ties, and other relevant factors.12 Longitudinal studies of 
the SwissDiab participants will be able to assess whether 
adherence to the SSED targets influences incidence of 
diabetes-related complications and comorbidities in this 
patient group.
The main limitation is that the study is based on two 
out of the six largest tertiary diabetes care centers in the 
German-speaking part of Switzerland. Although similar 
hospital standards and access to care are expected, 
the generalizability of the results to tertiary care in the 
German-speaking part and Switzerland as a whole is 
unclear. To what extent the enrolled patients are repre-
sentative of the patient group at large at the two centers 
is also not known, but currently under investigation. A 
further limitation is that not all of the SSED criteria could 
be assessed due to lack of information on physical activity 
and smoking cessation counseling, and the inability to 
provide meaningful data on the performance of nephrop-
athy screenings and foot exams that would be represen-
tative of the general clinical practice at the tertiary care 
centers involved, as these two exams are an integral parts 
of the annual SwissDiab examination.
As patients treated at tertiary care centers are more 
likely to present with advanced disease stages and 
diabetes-related complications, the study population 
represents a patient group that generally requires a large 
proportion of healthcare resources. It is thus important 
to obtain information on the status of quality of care 
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and treatment in this patient group. Next to CoDiab-VD, 
SwissDiab is the largest observational study in Switzer-
land including patients with DM1 and DM2. The longi-
tudinal setting and standardized annual examinations 
gain advantage over the CoDiab-VD Study, which is 
based largely on self-report. SwissDiab is thus a resource 
that has the potential to provide comprehensive and 
significant information on diabetes care in Switzerland. 
This will be of vital importance for decision makers in 
politics and the health sector in view of rising patient 
numbers and limited financial resources. As additional 
study centers are recruited, including the other language 
regions, SwissDiab will continue to give an even more 
complete picture on the quality of diabetes care and 
patient outcomes in Switzerland in the future.
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